Q-VANT’s mission is to develop and produce adjuvants to help global health priorities in prevention and eradication of diseases.
Commercial vaccines
Malaria
Saponin adjuvants have been able to significantly enhance the immune response, and enabled the only vaccines approved by WHO against this deadly disease.
Respiratory Syncytial Virus, Shingles
Recombinant vaccines adjuvanted with a liposomal system of QS-21 + MPLA.
SARS-CoV-2
VLP vaccine containing saponin adjuvant formulated into a Matrix of Immune Stimulating Complexes.
Development of a Saponin dmLT oral Adjuvant
The National Institutes of Health (NIH) has awarded a contract up to $9.2 million to Tulane University to collaborate with Q-Vant to develop a promising new adjuvant for oral vaccines that can be delivered via a pill or dissolved beneath the tongue, eliminating the need for injections.
Massive clinical studies
QS-21 and saponin adjuvants carry more than 30 years of evaluation in for human vaccines and have been studied for immunizations against at least 65 infectious and non-infectious human diseases. Clinical trials have been conducted on patients across all genders, ages, across more than 76 countries from all continents, and with diverse genotypes.
Safety profile
QS-21 molecules and broader fractions have shown a safe profile in clinical trials, presenting similar incidence rate in the adjuvanted and placebo groups. Systemic adverse events induced by QS-21 may be diarrhea and headache, while local site reactions may result more severe and of longer duration.
Mechanism of action
Saponin adjuvants are immunostimulatory adjuvants and generate a biological effect, in both innate cellular and adaptive immune responses. Saponins are capable of activating CD4+ and CD8+ T cells, as well as inducing cross presentation.
Saponins interact directly with the CD2 surface receptor of T cells and QS-21 has been identified as a potential TLR4 agonist.
QS-21 INFINITY
Powered by Q-SAP Technology
QS-21 INFINITY characteristics:
Regulatory: Same molecule obtained from Quillaja biomass, no regulatory gap is expected.
Sample for preclinical studies
SPI Pharma, our strategic partner can deliver QS-21 INFINITY for preclinical studies. Samples are readily available.
Q-VANT team can provide expertise on vaccine formulations with QS-21 INFINITY.
QS-21 INFINITY offers the guarantee of a secure supply and volume for vaccines.
Proliferation of CD4+ T cells re-stimulated with OVA
Activated CD4+ T cells expressing CD25
Cellular response
- QS-21 INFINITY standalone potentiates the proliferative capacity and activation of CD4+ T cells and antigen specific CD4 + T cells.
- QS-21 INFINITY standalone shows statistically none or slightly better performance than QS-21 standard.
QS-Oral
Adjuvants and antigens suitable for inducing immune response via mucosal administration are scarce.
QS-ORAL saponin adjuvant provides a broad adjuvant effect due to the multiple saponin components and is intended for use in vaccine formulations for oral or sublingual route of application.
Many published studies on animals have employed Quillaja saponins as oral adjuvants. These publications have employed the saponins either in conjunction with parentally delivered antigens or as a booster. A number of antigens were evaluated, including TT, KLH, CPMV, OVA, RSV, HBsAG, NVCP, and HA. These investigations’ outcomes confirm animal safety while enhancing antigen-specific immunity.
Development of a Saponin dmLT Oral Adjuvant
The National Institutes of Health (NIH) has awarded a contract up to $9.2 million to Tulane University to collaborate with Q-Vant to develop a promising new adjuvant for oral vaccines that can be delivered via a pill or dissolved beneath the tongue, eliminating the need for injections.
